Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial
Strober B, Sobell J, Duffin K, Bao Y, Guérin A, Yang H, Goldblum O, Okun M, Mulani P. Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial. British Journal Of Dermatology 2012, 167: 1374-1381. PMID: 22897348, DOI: 10.1111/bjd.12000.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesDermatology Life Quality IndexHealth-related qualitySleep impairmentSleep qualityAdalimumab treatmentSuboptimal responseWork productivitySleep measuresMedical Outcomes Study Sleep ScalePoor health-related qualityGlobal assessmentPhase IIIb trialChronic plaque psoriasisPhysician global assessmentEffect of adalimumabDisease-related painVisual analog scaleLife Quality IndexIIIb trialPrior therapyPsoriasis signsPlaque psoriasisPresence of PSAPsoriasis Area